Silence Therapeutics Plc American Depository Share (SLN) Stock Price

SLNStock

$13.42−72.00%52W

Market Cap$834.11M

P/E—

PEG Ratio—

Div yield—

Beta2.74

SLN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-36.42%

Price vs S&P 500 (4W)163.61%

VGM Score24.99

Book Value / Share (Quarterly)$0.44

P/TBV (Annual)26.24x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)315.49%

Price vs S&P 500 (YTD)96.57%

Gross Margin (TTM)79.50%

Net Profit Margin (TTM)-8943.86%

EPS (TTM)$-0.53

10-Day Avg Trading Volume0.00M

EPS Excl Extra (TTM)$-0.53

Revenue Growth (5Y)305.31%

ROI (Annual)-48.53%

Gross Margin (Annual)37.83%

Net Profit Margin (5Y Avg)-422.12%

Cash / Share (Quarterly)$0.08

Revenue Growth QoQ (YoY)-99.92%

ROA (Last FY)-39.75%

Revenue Growth TTM (YoY)-99.27%

EBITD / Share (TTM)$-0.54

ROE (5Y Avg)-135.82%

Operating Margin (TTM)-9345.05%

Cash Flow / Share (Annual)$-0.52

P/B Ratio10.30x

P/B Ratio (Quarterly)4.66x

Net Income / Employee (Annual)$-490,657,800,000

EV / Revenue (TTM)1511.59x

Net Interest Coverage (TTM)-15.11x

ROA (TTM)-56.37%

EPS Incl Extra (Annual)$-0.53

Current Ratio (Annual)4.46x

Quick Ratio (Quarterly)8.06x

3-Month Avg Trading Volume0.00M

52-Week Price Return-72.00%

Revenue / Employee (TTM)$9,500

Tangible BV / Share (Quarterly)$0.44

P/S Ratio (Annual)20.61x

Asset Turnover (Annual)0.17x

52-Week High$5.99

Operating Margin (5Y Avg)-486.99%

EPS Excl Extra (Annual)$-0.53

CapEx CAGR (5Y)149.02%

Tangible BV CAGR (5Y)-20.87%

26-Week Price Return-31.07%

13-Week Price Return7.05%

Total Debt / Equity (Annual)2.02x

Current Ratio (Quarterly)8.72x

Enterprise Value$630.33M

Revenue / Share Growth (5Y)279.98%

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-22.83%

Revenue / Employee (Annual)$212,082,300,000

Pretax Margin (Annual)-270.66%

Cash / Share (Annual)$0.83

3-Month Return Std Dev95.52%

Net Income / Employee (TTM)$-852,700

ROE (Last FY)-264.65%

Net Interest Coverage (Annual)-6.60x

EPS Basic Excl Extra (Annual)$-0.53

Receivables Turnover (TTM)0.86x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.53

Receivables Turnover (Annual)28.09x

ROI (TTM)-103.26%

P/S Ratio (TTM)764.73x

Pretax Margin (5Y Avg)-484.47%

Revenue / Share (Annual)$0.23

Tangible BV / Share (Annual)$0.16

Price vs S&P 500 (52W)-75.27%

Year-to-Date Return100.00%

5-Day Price Return-11.11%

EPS Normalized (Annual)$-0.53

ROA (5Y Avg)-43.18%

Net Profit Margin (Annual)-231.35%

Month-to-Date Return166.67%

Cash Flow / Share (TTM)$-0.33

Operating Margin (Annual)-277.66%

LT Debt / Equity (Annual)1.19x

ROI (5Y Avg)-53.35%

LT Debt / Equity (Quarterly)0.57x

EPS Basic Excl Extra (TTM)$-0.53

P/TBV (Quarterly)4.68x

P/B Ratio (Annual)3.53x

Pretax Margin (TTM)-8942.55%

Book Value / Share (Annual)$0.26

Price vs S&P 500 (13W)3.44%

Beta2.74x

Revenue / Share (TTM)$0.01

ROE (TTM)-103.26%

52-Week Low$1.06

vGradeF

gGradeD

mGradeD

vgmGradeD

SLN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	-$0.11	-$0.27	-145.45%(-$0.16)
Q1 2026	May 7, 2026	-$0.09	-$0.33	-266.67%(-$0.24)
Q4 2025	Mar 5, 2026	-$0.49	-$0.27	+44.90%(+$0.22)
Q3 2025	Nov 6, 2025	-$0.21	-$0.15	+27.42%(+$0.06)
Q2 2025	Aug 7, 2025	-$0.18	-$0.57	-219.33%(-$0.39)

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
SLNSilence Therapeutics Plc American Depository Share	F	D	D	$13.42
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Silence Therapeutics Plc American Depository Share

Silence Therapeutics is a biotechnology company developing short-interfering RNA (siRNA) therapeutics using its proprietary mRNAi GOLD platform. The company's pipeline targets cardiovascular disease, hematology, and rare diseases, with lead candidates Divesiran for hematological disorders and Zerlasiran for cardiovascular conditions. Silence also generates revenue through out-licensed programs with third-party collaborators.